ライフサイエンスコーパス: plasma exchange

1 ncreases observed in TTP patients treated by plasma exchange.

2 gnosed clinically with PTMA and treated with plasma exchange.

3 Three patients also received plasma exchange.

4 ficult cases or before thymectomy in lieu of plasma exchange.

5 compared with those receiving no therapeutic plasma exchange.

6 hout plasma exchange treatment, and risks of plasma exchange.

7 gs, danazol, intravenous immunoglobulin, and plasma exchange.

8 in is equivalent to but more convenient than plasma exchange.

9 peutic plasma exchange versus no therapeutic plasma exchange.

10 ive supportive therapy, including low-volume plasma exchange.

11 cyclophosphamide, oral glucocorticoids, and plasma exchange.

12 hypogammaglobulinaemia and during the first plasma exchange.

13 ednisolone, intravenous immunoglobulins, and plasma exchange.

14 ducting a direct membrane-feeding assay with plasma exchange.

15 ulmonary haemorrhage would choose to receive plasma exchange.

16 compared with no change with no therapeutic plasma exchange.

17 ith this disorder need urgent treatment with plasma exchange.

18 -eight percent were refractory to first-line plasma exchange.

19 e-pass albumin dialysis, blood exchange, and plasma exchange.

20 vant clinical indications and precautions of plasma exchange.

21 ytokines, and improved severity scores after plasma exchange.

22 ited efficacy, include immunosuppression and plasma exchange.

23 anti-SARS-CoV-2 IVIg (1 trial), therapeutic plasma exchange (1 trial), XAV-19 polyclonal antibody (1

24 ough 10 of the 11 patients had a response to plasma exchange, 2 required 20 or more exchanges before

25 required regular intravenous immunoglobulin/plasma exchange.75% of patients had a mean reduction in

26 cyclophosphamide and corticosteroids (83%), plasma exchange (9%), and biologic agents (after 2002; 1

27 d dramatically with the initiation of prompt plasma exchange, a treatment routinely used without any

28 torical survivors who were given therapeutic plasma exchange alone or with vincristine.

29 ld determine whether adjuvant rituximab with plasma exchange also is beneficial at first diagnosis.

30 ety-seven patients (91.5%) were treated with plasma exchange and 50 patients (47.2%) received eculizu

31 ently with immunosuppression and therapeutic plasma exchange and continued until ADAMTS13 recovery, r

32 Plasma exchange and continuous renal replacement therapy

33 Upfront treatment of acute TTP includes plasma exchange and corticosteroids.

34 resolved upon the remission that accompanied plasma exchange and discontinuation of ticlopidine thera

35 caplacizumab (10 mg daily) or placebo during plasma exchange and for 30 days afterward.

36 0 mg daily subcutaneously) or placebo during plasma exchange and for 30 days thereafter.

37 The PEXIVAS (Plasma Exchange and Glucocorticoids in Severe Antineutro

38 tients who received caplacizumab needed less plasma exchange and had a shorter hospitalization than t

39 scontinuation of the drug and treatment with plasma exchange and has not recurred during 10 months of

40 dium succinate and alternate treatment using plasma exchange and immunoabsorption as well as subseque

41 Daily plasma exchange and immunosuppressive therapies induce r

42 investigated whether NAC, without concurrent plasma exchange and immunosuppressive therapy, is effect

43 hylaxis with eculizumab or standard of care (plasma exchange and intravenous Ig) at ten international

44 Variable regimes of steroids, plasma exchange and intravenous immunoglobulin were asso

45 rials have shown equivalent efficacy of both plasma exchange and intravenous immunoglobulin, but not

46 Effective treatments include plasma exchange and intravenous immunoglobulins.

47 Plasma exchange and IVIG were both effective in lessenin

48 essively than late with more frequent use of plasma exchange and monoclonal/polyclonal antibodies.

49 Organ Dysfunction scores between therapeutic plasma exchange and no therapeutic plasma exchange diffe

50 Our NMA suggests that plasma exchange and polymyxin-B hemoperfusion may provid

51 rrence after kidney transplant, resistant to plasma exchange and rituximab treatment that subsequentl

52 Immunosuppressive treatment combining plasma exchange and rituximab was associated with improv

53 ith acquired TTP respond to a combination of plasma exchange and rituximab, but some die or acquire i

54 reated with intravenous steroids followed by plasma exchange and rituximab.

55 age without kidney involvement would decline plasma exchange and that all or almost all (>=90%) fully

56 What is the role of plasma exchange and what is the optimal dose of glucocor

57 purpura who responded poorly to therapeutic plasma exchange and who were treated with rituximab had

58 en in the oncology patient do not respond to plasma exchange and, where feasible, treatment of the un

59 igh-dose intravenous steroids in addition to plasma exchange and/or intravenous immunoglobulin.

60 Despite the use of plasma exchanges and intravenous immunoglobulins, Guilla

61 nflammatory syndrome (IRIS), 11 patients had plasma exchange, and 2 had immunoabsorption.

62 ed with methylprednisolone sodium succinate, plasma exchange, and azathioprine and has remained in re

63 supportive therapies, including therapeutic plasma exchange, and demonstrated progression of liver i

64 fication techniques including hemoperfusion, plasma exchange, and hemofiltration with hemoperfusion w

65 ating therapies, including immunoadsorption, plasma exchange, and high-dose intravenous immunoglobuli

66 corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants) and ambulatory

67 The role of stem cell transplantation, plasma exchange, and kidney transplantation in the manag

68 abilized under therapy with corticosteroids, plasma exchange, and mitoxantrone, severe cognitive impa

69 are investigating the roles of methotrexate, plasma exchange, and pulse cyclophosphamide in acute dis

70 0 with high-dose intravenous immunoglobulin, plasma exchanges, and eventually rituximab.

71 All patients received a minimum of seven plasma exchanges, and the median cumulative doses of rit

72 presentations of TTP, which are treated with plasma exchange, anticoagulation is the most important t

73 eroids, intravenous immunoglobulin (IVIG) or plasma exchange are each effective in about two-thirds o

74 taneous immunoglobulin, corticosteroids, and plasma exchange are effective treatments, but maintenanc

75 Intravenous immunoglobulin and plasma exchange are fast-acting treatments used for dise

76 icosteroids, intravenous immunoglobulin, and plasma exchange are the most commonly used treatments fo

77 Response rates to current therapies (mainly plasma exchange) are unsatisfactory.

78 essive agents often used in combination with plasma exchange, are less well defined.

79 ese findings provide a rationale to consider plasma exchange as a therapeutic option in COVID-19 and

80 ticoids, intravenous immunoglobulins, and/or plasma exchange at some point in their illness.

81 Treatment with plasma exchange, available for more than 20 years, has d

82 ther immunosuppressive agents in addition to plasma exchange but who have a high risk for relapse.

83 e that often could be treated effectively by plasma exchange, but without real understanding of the u

84 Plasma exchange can be helpful in selected patients.

85 er support systems, particularly therapeutic plasma exchange, can be useful for patients with ALF, es

86 II, non-blinded randomised control trial of plasma exchange compared to standard of care in critical

87 s lower in children treated with therapeutic plasma exchange compared with those receiving no therape

88 as within 30 days of completing therapeutic plasma exchange) compared with placebo (risk difference

89 Plasma exchange, complement C3 and C3b inhibition, and r

90 ence in the diagnosis to justify the risk of plasma exchange complications.

91 Therapeutic plasma exchange continues to be indicated for idiopathic

92 Therapeutic plasma exchange continues to be reported sporadically in

93 ar CLIA seems able to reliably avert empiric plasma exchange, corticosteroids, and caplacizumab in pa

94 rompt initiation of therapy with therapeutic plasma exchange, corticosteroids, and rituximab improves

95 Treatment with therapeutic plasma exchange, corticosteroids, and rituximab is assoc

96 Treatments have usually consisted of plasma exchange, corticosteroids, intravenous immunoglob

97 erapeutic plasma exchange and no therapeutic plasma exchange differed in temporal pattern during the

98 ines the literature published on therapeutic plasma exchange during 2002.

99 In the acute situation plasma exchange, fat-free parenteral nutrition and acute

100 drome, were randomly assigned treatment with plasma exchange (five single-volume exchanges over 2 wee

101 py and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control.

102 PEX were treated with a daily single volume plasma exchange for a minimum of five days.

103 gnosis; however, treatment with steroids and plasma exchange for acute attacks and with immunosuppres

104 for a clinical trial testing the efficacy of plasma exchange for children with septic shock and TAMOF

105 The literature confirms the use of plasma exchange for Guillain-Barre syndrome but suggests

106 he period, reviews of the use of therapeutic plasma exchange for managing Guillain-Barre syndrome and

107 eated with plasma obtained after therapeutic plasma exchange for recurrent pFSGS led to lower cell de

108 Finally, plasma exchange for Wegener granulomatosis with severe r

109 and 51 (73%) of 70 and 35 of (50%) 70 in the plasma exchange group, respectively.

110 At 1 month, the IVIG and plasma exchange groups showed striking improvements in o

111 Plasma exchange has a confirmed place in therapy.

112 Plasma exchange has been proved to be the most important

113 Plasma exchange has improved survival rates from 10% to

114 For the treatment of AAV, plasma exchange has no important effect on mortality, re

115 ve studies of intravenous immunoglobulin and plasma exchange have not been performed.

116 Intravenous immunoglobulins and plasma exchange have unproven benefits, but may provide

117 Treatment of iTTP includes plasma exchange, high-dose glucocorticoids, rituximab, a

118 These patients require plasma exchange, i.e., concurrent replacement of the inh

119 The systematic review of plasma exchange identified nine randomised controlled tr

120 ments that also remove IgG (plasma donation, plasma exchange, immunoadsorption); (c) diseases resulti

121 Plasma exchange improves renal recovery rates in severe

122 ne recommendations vary regarding the use of plasma exchange in AAV and lack explicit recommendations

123 Future pathways need to replace plasma exchange in acute TTP and optimize/personalize rA

124 estions about the rationale for and value of plasma exchange in ADAMTS13 nondeficient patients.

125 cytotoxic drug therapy with the addition of plasma exchange in disease induced by antibody to glomer

126 eCIPE-M1 (Rescuing Cancer Immunotherapy with Plasma Exchange in Melanoma 1).

127 d controlled trials investigating effects of plasma exchange in patients with AAV or pauci-immune rap

128 ne panel makes a weak recommendation against plasma exchange in patients with low or low-moderate ris

129 SKD), and a weak recommendation in favour of plasma exchange in patients with moderate-high or high r

130 supportive care, but also immunosuppression, plasma exchange in severe cases and dialysis as needed.

131 vided a compelling rationale for therapeutic plasma exchange in some patients with thrombotic thrombo

132 1978, after performing the first studies on plasma exchange in that disease, he established a myasth

133 acute renal failure requiring intubation and plasma exchange in the intensive care setting.

134 The proper role of therapeutic plasma exchange in the treatment of autoimmune hemolytic

135 Recent reports on the value of plasma exchange in the treatment of severe antineutrophi

136 Finally, a large case series of the use of plasma exchange in Wegener granulomatosis was published.

137 Discontinuation of cyclosporine and daily plasma exchange increased the ADAMTS13 activity, which w

138 Plasma exchange increased the rate of renal recovery in

139 rials including 908 participants showed that plasma exchange increased the risk of serious infections

140 t patients, regardless of mutational status, plasma exchange/infusion use, platelet count, or lactate

141 and receiving standard treatment, including plasma exchange, intravenous Ig, and rituximab.

142 Plasma exchange, intravenous immunoglobulin and corticos

143 Syndrome (GBS) enrolled in a trial comparing plasma exchange, intravenous immunoglobulin, and both tr

144 Therapeutic plasma exchange is an effective empiric treatment for th

145 Early treatment with steroids and plasma exchange is associated with reduced likelihood of

146 A major unanswered question is whether plasma exchange is effective for the subset of patients

147 ally similar syndromes for which therapeutic plasma exchange is not or may not be beneficial.

148 Treatment with plasma exchange is often effective but does not address

149 Plasma exchange is the most effective initial therapy fo

150 Treatment with intravenous immunoglobulin or plasma exchange is the optimal management approach, alon

151 The role of plasma exchange is uncertain, but this treatment is appr

152 Plasma exchange leads to functionally important neurolog

153 er than 5% but no inhibitor at presentation, plasma exchange led to complete clinical remission and a

154 of patients with severe sepsis suggests that plasma exchange may benefit a subset of patients, those

155 ney involvement, based on indirect evidence, plasma exchange may have little or no effect on death (v

156 symptoms were also significantly improved by plasma exchange (mean change on Tourette syndrome unifie

157 This case suggests that IVCY and plasma exchange might be effective therapeutic options f

158 lism in patients with myeloma indicated that plasma exchange might remove only 25% of the total amoun

159 Plasma exchange mitigates cytokine storm, reverses organ

160 lopidine or clopidogrel therapy, therapeutic plasma exchange must be promptly instituted to enhance l

161 7), intravenous immunoglobulin (n = 3), and plasma exchange (n = 1).

162 /dl) were randomly assigned to receive seven plasma exchanges (n = 70) or 3000 mg of intravenous meth

163 Ten received plasma exchange, nine IVIG, and ten placebo.

164 ed on plasma infusion for congenital TTP, or plasma exchange, often in combination with immunosuppres

165 There were no important effects of plasma exchange on all-cause mortality (relative risk 0.

166 The effects of plasma exchange on other outcomes were uncertain or cons

167 cs analyses allow us to detect the effect of plasma exchanges on both plasma and RBCs and demonstrate

168 th cyclophosphamide and corticosteroids, but plasma exchange only if autoantibodies rebounded.

169 ve ischemic organ injury without therapeutic plasma exchange or caplacizumab), 16% of patients have a

170 of more than 25% for at least 8 weeks during plasma exchange or infusion (in trial 2) were recruited.

171 Plasma exchange or infusion may transiently maintain nor

172 o decrease in the platelet count of >25%, no plasma exchange or infusion, and no initiation of dialys

173 spond to immunomodulatory treatments such as plasma exchange or intravenous immunoglobulin (IVIG).

174 We studied whether plasma exchange or IVIG would be better than placebo (sh

175 imab and cyclosporine in cases refractory to plasma exchange or resistant to the tapering of plasma e

176 ids; 43, intravenous immunoglobulin; and 13, plasma exchange; or a combination of these treatments.

177 ected adult participants, those treated with plasma exchange (PE) improved significantly more on this

178 The effect of plasma exchange (PE) on clinical outcome, suPAR levels,

179 rejection (AMR) is based on a combination of plasma exchange (PE), IVIg, corticosteroids (CS), and ri

180 ing high-dose corticosteroids, mitoxantrone, plasma exchange (PE), rituximab (anti-CD20), and alemtuz

181 ld enhance the efficacy of DSA removal using plasma exchange (PE).

182 Plasma exchange (PE, four to seven treatments per patien

183 h-dose intravenous steroids (HD-S; n = 810), plasma exchange (PE; n = 192), immunoadsorption (IA; n =

184 Initial treatment consisted of plasma exchanges (PE), high doses of calcineurin inhibit

185 ed thrombotic microangiopathy, and intensive plasma exchange (PEx) both replenishes ADAMTS-13 and imp

186 tic thrombocytopenic purpura (iTTP) has been plasma exchange (PEX) combined with immunomodulatory str

187 delay in ADAMTS13 activity restoration after plasma exchange (PEX) suspension.

188 Sixteen of 19 patients were treated with plasma exchange (PEX) therapy, with 6/16 (38%) respondin

189 AMTS13 activity >30% at median 31 days after plasma exchange (PEX), compared with 11.5 days in the no

190 th high doses of corticosteroids followed by plasma exchange (PLEX) and present results of a systemat

191 rom the PEXIVAS trial challenged the role of plasma exchange (PLEX) in ANCA-associated vasculitides (

192 The article reviews the use of plasma exchange (PLEX) in the management of the antineut

193 Therapeutic plasma exchange (PLEX) is an adjunctive treatment for pa

194 Management of PML has routinely used plasma exchange (PLEX) or immunoabsorption to hasten cle

195 hods: PEXIVAS randomized 704 participants to plasma exchange (PLEX) or no-PLEX and reduced or standar

196 with I+R (n = 25), or, in more severe ABMR, plasma exchange (PLEX)+I+R (n = 20).

197 imab (RTX) versus cyclophosphamide (CYC) and plasma exchange (PLEX).

198 To retrospectively analyze the effect of plasma exchange (PLEX; yes = PLEX(+) , no = PLEX(-) ) an

199 Plasma exchange probably has little or no effect on mort

200 Plasma exchange probably reduces the one year risk of ES

201 re intensive therapies including twice-daily plasma exchange; pulses of cyclophosphamide, vincristine

202 Plasma exchange reduced circulating levels of soluble B7

203 cipants that reported ESKD demonstrated that plasma exchange reduced the risk of ESKD at 12 months (r

204 Plasma exchange reduces levels of B7 in sera from patien

205 Early treatment by plasma exchange reduces serum FLC concentrations, but ra

206 unresponsive to standard therapy (including plasma exchange), renal replacement therapy was successf

207 ion, and/or plasmapheresis with fresh-frozen plasma exchange, resolved TMA in most patients (57%).

208 ticosteroids, intravenous immunoglobulin, or plasma exchange) respond faster to treatment and less fr

209 cluding rituximab and repetitive therapeutic plasma exchanges resulted in effective and sustainable r

210 , 0.50-0.80]; p<0.001; 10 trials, n=557) and plasma exchange (risk ratio, 0.63 [95% CI, 0.42-0.96]; p

211 r antirejection treatment: group I (n = 10), plasma exchange-Rituximab; group II (n = 8), Bortezomib;

212 tive risk [RR]: 0.70; 95% CI, 0.57-0.86) and plasma exchange (RR: 0.61; 95% CI, 0.42-0.91) were assoc

213 The use of plasma exchange seemed to reduce anti-PF4/polyanion leve

214 and after each renal-replacement therapy or plasma exchange session.

215 " improved over baseline (seven of eight for plasma exchange, seven of nine for IVIG).

216 Evidence suggests that plasma exchange should be added to those with more sever

217 Plasma exchange should be promptly initiated before cyto

218 In severe cases, plasma exchange should be used for clearing autoantibodi

219 One patient died despite undergoing plasma exchange soon after diagnosis.

220 TTP, and discuss use of rituximab, increased plasma exchange, splenectomy, and immunosuppressive opti

221 relapsing thrombotic microangiopathy despite plasma exchange; splenectomy; and therapy with vincristi

222 for acute TTP is based on daily therapeutic plasma exchange supplying deficient ADAMTS13, with or wi

223 rovement of some affected children following plasma exchange that removed circulating GluR3 antibodie

224 Despite the success of plasma exchange the risk of relapse is high.

225 ide a rationale for the previously empirical plasma exchange therapy (removal of the inhibitory antib

226 universally fatal until the introduction of plasma exchange therapy in the 1970s.

227 3 activity in the context of the response to plasma exchange therapy to identify patients whose diagn

228 nt prolonged or inappropriate treatment with plasma exchange therapy when it is less likely to be suc

229 sma exchange or resistant to the tapering of plasma exchange therapy.

230 imal anticoagulation, immunosuppression, and plasma exchange therapy.

231 icosteroids, intravenous immunoglobulin, and plasma exchange; there is a clear need to test new agent

232 The aim of this study was to evaluate if plasma exchange, through the removal of circulating medi

233 Here we utilize miniaturized plasma exchange to deliver labeled albumin to tissues in

234 A large randomized trial of the use of plasma exchange to treat sepsis also appeared.

235 on after DES with IVIG + rituximab +/- PLEX (plasma exchange) +/- tocilizumab.

236 ndard of care (SOC) treatment is therapeutic plasma exchange (TPE) alongside immunomodulation with st

237 n were preemptively treated with therapeutic plasma exchange (tPE) and a single dose of Rituximab.

238 treatment, reducing the need for therapeutic plasma exchange (TPE) and improving platelet count recov

239 The proper management with Therapeutic Plasma Exchange (TPE) and IV methylprednisolone improved

240 o or recurrent FSGS resistant to therapeutic plasma exchange (TPE) and/or rituximab.

241 Repeated therapeutic plasma exchange (TPE) has been advocated to remove hepar

242 Therapeutic plasma exchange (TPE) has been successfully used to trea

243 Therapeutic plasma exchange (TPE) has the potential to improve the P

244 P >2 weeks after thienopyridine, therapeutic plasma exchange (TPE) increased likelihood of survival (

245 Therapeutic plasma exchange (TPE) is a useful adjunct in the managem

246 We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation

247 Therapeutic plasma exchange (TPE) remains a primary therapy for addr

248 underwent one or two courses of therapeutic plasma exchange (TPE) with subsequent complete resolutio

249 line triplet regimen associating therapeutic plasma exchange (TPE), immunosuppression with corticoste

250 US/TTP during this outbreak with therapeutic plasma exchange (TPE).

251 e and after one plasma volume of therapeutic plasma exchange (TPE).

252 failure underwent a total of 243 therapeutic plasma exchanges (TPE).

253 fore and after antibody removal (therapeutic plasma exchange [TPE] or ABO-A-trisaccharide immunoadsor

254 s (95% CI, -10.8 to -5.1) in the therapeutic plasma exchange-treated group compared with no change wi

255 udies have suggested the lack of efficacy of plasma exchange treatment and have identified other tran

256 ADAMTS13 was measured before beginning plasma exchange treatment in 142 (88%) of 161 consecutiv

257 diagnostic criteria, high mortality without plasma exchange treatment, and risks of plasma exchange.

258 The diagnosis of TTP is an indication for plasma exchange treatment, but beginning treatment requi

259 at has not changed since the introduction of plasma exchange treatment.

260 iagnosed with TTP-HUS and who may respond to plasma exchange treatment.

261 activity categories apparently responded to plasma exchange treatment.

262 severe ADAMTS13 deficiency may benefit from plasma exchange treatment; in addition, some patients wi

263 rapies for FSGS recurrence mostly consist of plasma exchange treatments, also for prolonged time, and

264 Plasma exchange typically resolves hematologic abnormali

265 Therapeutic plasma exchange use in thrombocytopenia-associated multi

266 tiple organ failure who received therapeutic plasma exchange versus no therapeutic plasma exchange.

267 increased plasma creatinine level, and total plasma exchange volume were independently associated wit

268 ompared with intravenous methylprednisolone, plasma exchange was associated with a reduction in risk

269 Plasma exchange was associated with increased likelihood

270 Use of therapeutic plasma exchange was associated with reduced 28-day morta

271 mprovement of respiratory failure, therefore plasma exchange was attempted, which demonstrated a bene

272 Plasma exchange was ceased in 62% of patients and intrav

273 Plasma exchange was effective in reducing VGKC antibody

274 s study investigated whether the addition of plasma exchange was more effective than intravenous meth

275 During cardiopulmonary bypass, plasma exchange was performed.

276 ic administration of NAC, without concurrent plasma exchange, was effective in preventing severe TTP

277 less so with intravenous immunoglobulins and plasma exchange-was associated with the most marked redu

278 al involvement, the panel suggests not using plasma exchange (weak recommendation).

279 dnisolone compared with 48 (69%) or 70 after plasma exchange were alive and independent of dialysis (

280 such as corticosteroids, immunoglobulin and plasma exchange were efficacious and safe.

281 patients desensitized with IVIG+rituximab+/-plasma exchange were enrolled and randomized 1:1 to rece

282 andard or enhanced adsorption hemofilter and plasma exchange were of interest, representing the most

283 immune globulin + rituximab with or without plasma exchange were tested for total IgG and IgG1-4 by

284 Steroids, intravenous immunoglobulin, or plasma exchange were used in 100 (86%) patients at diagn

285 urs, to perform renal-replacement therapy or plasma exchange, were randomly allocated (1:1) to receiv

286 without pulmonary haemorrhage would decline plasma exchange, whereas most patients with moderate-hig

287 enefit from immunosuppressive therapy and/or plasma exchange, whereas patients with HIT need an alter

288 ugh approximately 80% of patients respond to plasma exchange, which removes autoantibody and replenis

289 ing, or use of intravenous immunoglobulin or plasma exchange within 4 weeks before randomisation, or

290 latelet count, with discontinuation of daily plasma exchange within 5 days thereafter.

291 zed, sham-controlled, double-masked study of plasma exchange without concomitant immunosuppressive tr